Compare · ABCL vs XBIT
ABCL vs XBIT
Side-by-side comparison of AbCellera Biologics Inc. (ABCL) and XBiotech Inc. (XBIT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABCL and XBIT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABCL is the larger of the two at $3.90B, about 65.7x XBIT ($59.5M).
- Both names hit the wire about 7 times in the past 4 weeks.
- ABCL has more recent analyst coverage (21 ratings vs 0 for XBIT).
- Company
- AbCellera Biologics Inc.
- XBiotech Inc.
- Price
- -
- -
- Market cap
- $3.90B
- $59.5M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2015
- News (4w)
- 7
- 7
- Recent ratings
- 21
- 0
AbCellera Biologics Inc.
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. As of December 31, 2020, the company had 103 discovery programs that are either completed, in progress, or under contract. It has a discovery partnership agreement with Eli Lilly and Company. AbCellera Biologics Inc. was founded in 2012 and is headquartered in Vancouver, Canada.
XBiotech Inc.
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of antibody therapies for treating oncology, inflammatory conditions, and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and True Human COVID-19 therapy for treating the COVID-19 mutant virus. In addition, the company provides clinical trial contract research operations to conduct two large, double-blind placebo-controlled Phase II clinical studies. The company was incorporated in 2005 and is headquartered in Austin, Texas.
Latest ABCL
- Large owner Thermopylae Holdings Ltd. bought $698,920 worth of shares (60,565 units at $11.54), increasing direct ownership by 0.11% to 56,194,662 units (SEC Form 4)
- SEC Form 10-Q filed by AbCellera Biologics Inc.
- AbCellera Biologics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- AbCellera Reports Q3 2026 Business Results
- AbCellera to Present at the UBS Global Biopharma Conference on November 17, 2026
- AbCellera to Present at Upcoming Investor Conferences in November 2026
- AI Can Design Antibodies Faster Than Anyone Can Check Them for Immune Risk. That Gap Is Starting to Close.
- UBS initiated coverage on AbCellera Biologics with a new price target
- AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting
- AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026
Latest XBIT
- SEC Form 10-Q filed by XBiotech Inc.
- SEC Form 4 filed by XBiotech Inc.
- SEC Form 3 filed by XBiotech Inc.
- Director Simard John bought $711,251 worth of shares (368,524 units at $1.93) (SEC Form 4)
- SEC Form 8-K filed by XBiotech Inc.
- XBiotech Announces Election of Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers
- XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer
- SEC Form DEF 14A filed by XBiotech Inc.
- SEC Form 10-Q filed by XBiotech Inc.
- XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis